Aurobindo Pharma divests step-down subsidiary to Eris Pharma

10 Apr 2015 Evaluate

Aurobindo Pharma has divested its step-down subsidiary, Aurobindo Pharma (Australia) to Eris Pharma Australia. The pharma major will however under an agreement continue to manufacture and supply the products to Eris Pharma for Australian and New Zealand market over next few years.

This divestment is in line with Aurobindo’s strategy of focusing on US, EU and Key Emerging Markets. This subsidiary was not contributing any profit to the company.

Aurobindo Pharma manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company’s robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics, supported by an outstanding R&D set-up.


Aurobindo Pharma Share Price

1217.45 -6.20 (-0.51%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×